Ledger.Open graph →
SEC Form D · filed July 6, 2023

Aeglea BioTherapeutics, Inc

Offering
$210.0M
Sold
$210.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
AUSTIN, TX
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (20)

Tomas J. Kiselak · Austin, TXDirectorPeter J. Harwin · Austin, TXDirectorIvana J. Magovcevic-Liebisch · Austin, TXDirectorMichael J. Henderson · Austin, TXDirectorCameron Turtle · Austin, TXExecJonathan Alspaugh · Austin, TXExecAlison J. Lawton · Austin, TXDirectorHunter C. Smith · Austin, TXDirectorRussell J. Cox · Austin, TXDirectorCortney Caudill · Austin, TXExecTomas J. Kiselak · Austin, TXDirectorPeter J. Harwin · Austin, TXDirectorMichael J. Henderson · Austin, TXDirectorCameron Turtle · Austin, TXExecJonathan Alspaugh · Austin, TXExecAlison J. Lawton · Austin, TXDirectorIvana J. Magovcevic-Liebisch · Austin, TXDirectorHunter C. Smith · Austin, TXDirectorRussell J. Cox · Austin, TXDirectorCortney Caudill · Austin, TXExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗